Selecky of Immunitybio sells $250,000 in shares

Christobel Selecky, a director of ImmunityBio, Inc. (NASDAQ:IBRX), sold 25,000 shares of common stock on February 23, 2026, for $10 each, totaling $250,000, as the biotechnology company's cancer treatment ANKTIVA continues to show remarkable financial performance with a 700% revenue increase in 2025. The same day, Selecky exercised options to acquire 25,000 shares of ImmunityBio common stock at an exercise price of $2.98, for a total value of $74,500, with these options stemming from a stock option award. Following these transactions, Selecky directly holds 67,937 shares of the company, whose stock has surged 281% over the past year and currently trades at $11.54, near its 52-week high of $12.28. The sale was executed under a Rule 10b5-1 trading plan adopted on June 12, 2025, which allows directors and executives to sell shares according to a predetermined schedule, helping avoid accusations of insider trading. Despite the positive market performance, InvestingPro analysis indicates that ImmunityBio's stock appears overvalued relative to its Fair Value of $9.85, suggesting potential caution for investors. The company's financial success is driven by ANKTIVA, which generated $113 million in 2025, with fourth-quarter net product revenue reaching $38.3 million, up 20% from the third quarter. ImmunityBio has significantly expanded its market presence through strategic partnerships, including a collaboration with Accord Healthcare for distribution across 30 European countries following the European Commission's conditional marketing authorization, which allows the therapy to be marketed in 33 countries for BCG-unresponsive non-muscle invasive bladder cancer. Additionally, the company has partnered with Biopharma and Cigalah Healthcare to launch ANKTIVA in Saudi Arabia and the broader Middle East and North Africa region, with distribution expected to commence soon. Market analysts have responded positively to these developments, with H.C. Wainwright raising the stock price target for ImmunityBio to $15 while maintaining a Buy rating, reflecting confidence in the company's growth trajectory and product pipeline.